Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DERM
CUSIPN/A
Phone650-421-7200
Debt
Debt-to-Equity Ratio2.49
Current Ratio4.78
Quick Ratio4.78
Price-To-Earnings
Trailing P/E Ratio-2.42
Forward P/E Ratio-1.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.54 million
Price / Sales100.54
Cash FlowN/A
Price / CashN/A
Book Value$3.59 per share
Price / Book3.03
Profitability
EPS (Most Recent Fiscal Year)($4.39)
Net Income$-303,260,000.00
Net Margins-761.87%
Return on Equity-128.21%
Return on Assets-33.87%
Miscellaneous
Employees162
Outstanding Shares42,030,000
Market Cap$444.22 million
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira Inc (NASDAQ:DERM) issued its quarterly earnings results on Monday, August, 6th. The biopharmaceutical company reported ($0.57) EPS for the quarter, hitting the consensus estimate of ($0.57). The biopharmaceutical company had revenue of $39.08 million for the quarter, compared to analysts' expectations of $39 million. Dermira had a negative net margin of 761.87% and a negative return on equity of 128.21%. View Dermira's Earnings History.
When is Dermira's next earnings date?
What price target have analysts set for DERM?
6 Wall Street analysts have issued 1 year price objectives for Dermira's stock. Their forecasts range from $16.00 to $48.00. On average, they anticipate Dermira's stock price to reach $29.6667 in the next twelve months. This suggests a possible upside of 173.2% from the stock's current price. View Analyst Price Targets for Dermira.
What is the consensus analysts' recommendation for Dermira?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $20." (9/5/2018)
- 2. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/13/2018)
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Nabriva Therapeutics (NBRV), Zogenix (ZGNX), ACADIA Pharmaceuticals (ACAD), Akorn (AKRX), Clovis Oncology (CLVS), Corcept Therapeutics (CORT), Arrowhead Pharmaceuticals (ARWR), Aimmune Therapeutics (AIMT), Myovant Sciences (MYOV), Wave Life Sciences (WVE), Uniqure (QURE), ARMO Biosciences (ARMO) and Theravance Biopharma (TBPH).
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 66)
- Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 76)
- Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 50)
- Mr. Luis C. Peña, Chief Devel. Officer (Age 55)
- Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 41)
Has Dermira been receiving favorable news coverage?
News headlines about DERM stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dermira earned a news impact score of 0.18 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Dermira.
Who are Dermira's major shareholders?
Dermira's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Voya Investment Management LLC (2.85%), Orbimed Advisors LLC (2.45%), Dimensional Fund Advisors LP (1.48%), C WorldWide Group Holding A S (1.15%), Northern Trust Corp (1.01%) and First Midwest Bank Trust Division (0.78%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
Which major investors are selling Dermira stock?
DERM stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC, BlueMountain Capital Management LLC, NumerixS Investment Technologies Inc, Northern Trust Corp, Cubist Systematic Strategies LLC and Fox Run Management L.L.C.. Company insiders that have sold Dermira company stock in the last year include Christopher M Griffith, David E Cohen, Eugene A Bauer and Thomas G Wiggans. View Insider Buying and Selling for Dermira.
Which major investors are buying Dermira stock?
DERM stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, C WorldWide Group Holding A S, Dimensional Fund Advisors LP, Los Angeles Capital Management & Equity Research Inc., First Midwest Bank Trust Division, Engineers Gate Manager LP, Voya Investment Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $10.86.
How big of a company is Dermira?
Dermira has a market capitalization of $444.22 million and generates $4.54 million in revenue each year. The biopharmaceutical company earns $-303,260,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. Dermira employs 162 workers across the globe.
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (NASDAQ DERM)
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
